Since the study period, recommendations for genetic testing have evolved to include most women with ovarian cancer [29, 30], mainstreaming of genetic testing, and inclusion of a test to detect germline pathogenic BRCA1 or BRCA2 genetic variants in the MBS from 2017, at a cost of ~$1,000 per eligible person [31]. This evidence concerns the gene BRCA2 and ovarian cancer.